1. Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer.
- Author
-
Tahara, Junko, Shimizu, Kyoko, Otsuka, Nao, Akao, Junichi, Takayama, Yukiko, and Tokushige, Katsutoshi
- Subjects
- *
PACLITAXEL , *PANCREATIC cancer treatment , *MEDICATION safety , *POPULATION aging , *HOSPITAL care , *THERAPEUTIC use of antineoplastic agents , *PANCREATIC tumors , *SURVIVAL , *ALBUMINS , *FOLINIC acid , *RESEARCH , *RESEARCH methodology , *METASTASIS , *DEOXYCYTIDINE , *ANTINEOPLASTIC agents , *RETROSPECTIVE studies , *EVALUATION research , *MEDICAL cooperation , *FLUOROURACIL , *COMPARATIVE studies , *KAPLAN-Meier estimator - Abstract
Purpose: New chemotherapies have become available for the treatment of advanced pancreatic cancer and have led to changes in its standard treatments. Since pancreatic cancer is becoming more common as a result of population aging, there is a need for diversification of chemotherapy.Methods: Between March 2014 and April 2017, FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (G-nab) was used as first-line therapy to treat 27 patients with locally advanced and metastatic pancreatic cancer at our hospital. In this study, we retrospectively evaluated their clinical characteristics, survival outcomes and adverse events.Results: Twelve of the 27 patients were treated with FFX, and the other 15 patients were treated with G-nab. The disease control rate was 86.7% in the G-nab group and 75% in the FFX group. Median OS time was 8.9 months in the FFX group and 11.8 months in the G-nab group. The 1-year survival rate was 46.6% in the G-nab group and 16.6% in the FFX group. The second-line treatment rate was 40% in the G-nab group and 66.7% in the FFX group. The grade 3-4 neutropenia rate was 20% in the G-nab group and 25% in the FFX group. No patients developed febrile neutropenia, or severe nausea, diarrhea, or anorexia. The peripheral sensory neuropathy rate was 73.3% in the G-nab group and 75% in the FFX group.Conclusions: Although G-nab and FFX are effective treatments for advanced pancreatic cancer, the G-nab group had a higher 1-year survival rate, and G-nab can be more safely administered to older patients. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF